Due to the recent rise in immunotherapy research to treat Glioblastoma, immunocompetent mouse models have become increasingly crucial for the study of novel immunotherapies against brain tumors. However, the kinetics of the immune response against the most prevalent immunocompetent GBM models, GL261 and CT2A, have not been well studied, nor have they been compared adequately in the literature. In this study, we compared the immune response in these models using flow cytometry and immunohistochemistry. We investigated several factors that influence the immune response, such as kinetics, tumor size, and transfection status. We hypothesize that these factors influence the immune response enough to warrant consideration while studying new immunotherapeutic approaches for treating GBM. Our results will aid in the preclinical studies of immunotherapy for GBM by allowing scientists to make informed decisions about their chosen models.
Citation Format: Breanna R. Noffsinger, Alexandra Witter, Natasha Shebani, Aizhen Xiao, Qing Zhong, Tajie Harris, Benjamin Purow. The kinetics of the anti-glioblastoma immune response in immunocompetent mouse models is influenced by neglected factors [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2020 Oct 19-20. Philadelphia (PA): AACR; Cancer Immunol Res 2021;9(2 Suppl):Abstract nr PO056.